Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Lisata Therapeutics, Inc. (NASDAQ: LSTA)*, formerly, Caladrius Biosciences, Inc. (NASDAQ: CLBS) , formerly, NeoStem

Organization & Developments: NeoStem

Parents

Lisata Therapeutics, Inc. (NASDAQ: LSTA)*, formerly, Caladrius Biosciences, Inc. (NASDAQ: CLBS) , formerly, NeoStem

2018: Caladrius Biosciences: Cheap With Catalysts On The Way - Caladrius Biosciences, Inc. (NASDAQ:CLBS)
2021: Checking In On Caladrius Biosciences
Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly of cardiovascular disease.
Lisata Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases
NeoStem and the Schepens Eye Research Institute to Study NeoStem's VSEL™ Technology in Retinal Diseases (2010)
NeoStem, Inc. Awarded NIH Research Research Infrastructure 'Grand Opportunities' Grant
T-cell regulatory technology through the acquisition of Progenitor Cell Therapy, LLC.
The addition of PCT will allow NeoStem to focus on growing the cord blood and adult stem cell banking, cellular manufacturing and therapeutic business
The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology
VSEL technology uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells